

Docket No. CEN 5017 USNP

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: NAKADA ET AL

Serial No.: 10/808,699

Art Unit:

Filed

: MARCH 24, 2004

Examiner:

For

: USE OF EMMPRIN ANTAGONISTS FOR THE TREATMENT OF

DISEASES

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

MAY 10, 2005
(Date of Deposit)

KENNETH J. DOW

(Name of applicant, assignee, or Registered Representative)

MAY 10, 2005

(Signature)

(Date of Signature)

Commissioner for Patents P. O. BOX 1450 ALEXANDRIA, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with [] the
first or Second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-0750-
CEN5017USNP/KD the fee of \$180.00 as set forth
in §1.17(p).

 $\square$  In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

	Statement in Accordance with §1.97(e)						
	(attached); or						
$\boxtimes$	Please charge Deposit Account No. 10-						
	0750/CEN203NP/KD the fee of $$180.00$ as set forth						
	in §1.17(p).						
Disclosure State either a Final under §1.311 b Applicant(s) he Information Discharge with \$180.00 as set	excordance with §1.97(d), this Information sement is being filed after the mailing date of Action under §1.113 or a Notice of Allowance but before the payment of the Issue Fee. Except petition(s) for consideration of this aclosure Statement. Included are: Statement in §1.97(e) as set forth below and the fee of forth in §1.17(p).						
Copies of references listed on the attached Form PTO- 1449 are enclosed herewith EXCEPT THAT:							
	In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.						
	If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.						
☐ There	e are no listed references which are not in the						

The relevance of those listed references which are					
not in the English language is as follows:					
☐ Attached are copies of search report(s) from					
corresponding patent application(s), which are listed on the					
attached Submission Under MPEP 609 D.					
Attached are the following non-published pending					
patent applications which may be deemed relevant, which are					
listed on the attached Submission Under MPEP 609 D.					

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN5017USNP/KD. This form is submitted in triplicate.

Respectfully submitted,

KENNETH J. DOW Reg. No. 32,890

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (610)651-7422 DATED: MAY 10, 2005 MAY 1 6 2023 C

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

stitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Application Number	10/808,699
Filing Date	March 24, 2004
First Named Inventor	Marian Nakada
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 5017USNP

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or
		Kind Code <sup>2</sup>				
		Number (i	f known)	or oned bocarrier	mm-dd-yyyy	relevant figures appear
		2003/0027161	A1	Bejanin et al	02-06-2003	
	<b>.</b>					
			<del> </del>			
				•		
						N.
					\ \	

#### **FOREIGN PATENT DOCUMENTS** Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Cite T<sup>6</sup> passages or relevant Examiner mm-dd-yyyy Applicant of Cited Document figures appear Initials Office<sup>3</sup> Number<sup>4</sup> KindCode5 No.1

	 ···
Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

collection of information unless it displays a valid OND control number.				
Application Number	10/808,699			
Filing Date	MARCH 24, 2004			
First Named Inventor	MARIAN NAKADA			
Group Art Unit				
Examiner Name				
Attorney Docket Number	CEN5017USNP			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		
Examiner's	Cite	(book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>	
Initials*	No.1	publisher, city and/or country where published		
	1	ZUCKER, "Tumor Cell-Stormal Cell Interactions in Cancer," DEPT. OF VETERAN		
		AFFAIRS, 2004, 3 pages, USA.		
		ZUCKER ET AL, "Extracellular matrix metalloproteinase inducer (EMMPRIN)		
		facilitates tumor angiogenesis," AMERICAN ASSOCIATION FOR CANCER		
		RESEARCH ANNUAL MEETING, 1998, page 41, Vol. 39.		
		SAMESHIMA ET AL, "Glioma cell extracellular matrix metalloproteinase inducer		
		(EMMPRIN) (CD147) stimulates production of membrane-type matrix		
		metalloproteinases and activated gelatinase A in co-cultures with brain-derived		
		fibroblasts," Cancer lett., 2000, pp 177-184, vol. 157, No. 2.		
		ZUCKER ET AL, "Tumorigenic Potential of Extracellular Matrix Metalloproteinase		
1		Inducer," AMERICAN JOURNAL OF PATHOLOGY, 2001, pp 1921-1928, Vol. 158,		
		No. 6, American Society for Investigative Pathology.		
		LOOKSMART, "Emmprin - Its Role in Tumor Angiogenesis and Metastasis," Life		
1		Sciences and Biotechnology, 2001, Merton Allen Association and Gale Group.		
		M44		
<b> </b>	$\vdash$			
	$\vdash$			
	<b> </b>	·		

		the state of the s			
Examiner			Date		
Signature	ė.		Considered	1	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.